Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes

Leah Mellett; Gaya Amarasinghe; Christopher W. Farnsworth; Shabaana A. Khader

doi:10.1021/acsinfecdis.3c00249

Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes

Leah Mellett, Gaya Amarasinghe, Christopher W. Farnsworth, Shabaana A. Khader

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The alarmin calprotectin (S100A8/A9) is thought to drive a cytokine storm, a hallmark of severe COVID-19. Recent studies report circulating S100A8/A9 levels can distinguish COVID-19 severity but have only been conducted in non-U.S. cohorts and mainly focus on serum S100A8/A9 levels. Thus, we quantified S100A8/A9 in serum and urine samples from a hospital cohort in St. Louis, Missouri, to expand the understanding of S100A8/A9 as a prognostic biomarker for COVID-19. Elevated S100A8/A9 serum levels were observed in ICU patients (n = 49, p = 0.0370) and patients with fatal cases of COVID-19 (n = 76, p = 0.0018). We observed no correlation in the S100A8/A9 levels in matched serum and urine samples. Our results support the association of serum S100A8/A9 levels with COVID-19 severity and suggest that further investigation of urine S100A8/A9 as a COVID-19 biomarker is not warranted.

Original language	English
Pages (from-to)	1815-1820
Number of pages	6
Journal	ACS Infectious Diseases
Volume	9
Issue number	10
DOIs	https://doi.org/10.1021/acsinfecdis.3c00249
State	Published - Oct 13 2023

Keywords

COVID-19
S100A8/A9
biomarker
calprotectin
prognosis

Access to Document

10.1021/acsinfecdis.3c00249

Cite this

@article{921920ac5a4943798f14f0dc77d8d990,

title = "Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes",

abstract = "The alarmin calprotectin (S100A8/A9) is thought to drive a cytokine storm, a hallmark of severe COVID-19. Recent studies report circulating S100A8/A9 levels can distinguish COVID-19 severity but have only been conducted in non-U.S. cohorts and mainly focus on serum S100A8/A9 levels. Thus, we quantified S100A8/A9 in serum and urine samples from a hospital cohort in St. Louis, Missouri, to expand the understanding of S100A8/A9 as a prognostic biomarker for COVID-19. Elevated S100A8/A9 serum levels were observed in ICU patients (n = 49, p = 0.0370) and patients with fatal cases of COVID-19 (n = 76, p = 0.0018). We observed no correlation in the S100A8/A9 levels in matched serum and urine samples. Our results support the association of serum S100A8/A9 levels with COVID-19 severity and suggest that further investigation of urine S100A8/A9 as a COVID-19 biomarker is not warranted.",

keywords = "COVID-19, S100A8/A9, biomarker, calprotectin, prognosis",

author = "Leah Mellett and Gaya Amarasinghe and Farnsworth, {Christopher W.} and Khader, {Shabaana A.}",

note = "Publisher Copyright: {\textcopyright} 2023 American Chemical Society.",

year = "2023",

month = oct,

day = "13",

doi = "10.1021/acsinfecdis.3c00249",

language = "English",

volume = "9",

pages = "1815--1820",

journal = "ACS Infectious Diseases",

issn = "2373-8227",

number = "10",

}

TY - JOUR

T1 - Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes

AU - Mellett, Leah

AU - Amarasinghe, Gaya

AU - Farnsworth, Christopher W.

AU - Khader, Shabaana A.

PY - 2023/10/13

Y1 - 2023/10/13

N2 - The alarmin calprotectin (S100A8/A9) is thought to drive a cytokine storm, a hallmark of severe COVID-19. Recent studies report circulating S100A8/A9 levels can distinguish COVID-19 severity but have only been conducted in non-U.S. cohorts and mainly focus on serum S100A8/A9 levels. Thus, we quantified S100A8/A9 in serum and urine samples from a hospital cohort in St. Louis, Missouri, to expand the understanding of S100A8/A9 as a prognostic biomarker for COVID-19. Elevated S100A8/A9 serum levels were observed in ICU patients (n = 49, p = 0.0370) and patients with fatal cases of COVID-19 (n = 76, p = 0.0018). We observed no correlation in the S100A8/A9 levels in matched serum and urine samples. Our results support the association of serum S100A8/A9 levels with COVID-19 severity and suggest that further investigation of urine S100A8/A9 as a COVID-19 biomarker is not warranted.

AB - The alarmin calprotectin (S100A8/A9) is thought to drive a cytokine storm, a hallmark of severe COVID-19. Recent studies report circulating S100A8/A9 levels can distinguish COVID-19 severity but have only been conducted in non-U.S. cohorts and mainly focus on serum S100A8/A9 levels. Thus, we quantified S100A8/A9 in serum and urine samples from a hospital cohort in St. Louis, Missouri, to expand the understanding of S100A8/A9 as a prognostic biomarker for COVID-19. Elevated S100A8/A9 serum levels were observed in ICU patients (n = 49, p = 0.0370) and patients with fatal cases of COVID-19 (n = 76, p = 0.0018). We observed no correlation in the S100A8/A9 levels in matched serum and urine samples. Our results support the association of serum S100A8/A9 levels with COVID-19 severity and suggest that further investigation of urine S100A8/A9 as a COVID-19 biomarker is not warranted.

KW - COVID-19

KW - S100A8/A9

KW - biomarker

KW - calprotectin

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85174751737&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.3c00249

DO - 10.1021/acsinfecdis.3c00249

M3 - Article

C2 - 37787461

AN - SCOPUS:85174751737

SN - 2373-8227

VL - 9

SP - 1815

EP - 1820

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

IS - 10

ER -

Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this